Spero Therapeutics, Inc 10-K for FY2023
Spero Therapeutics, Inc. (SPRO)
10-K
2024-03-13
For: 2023-12-31
View Original
Added on
April 07, 2026
About this 10-K
Spero Therapeutics, Inc filed this 10-K on March 13, 2024, covering the fiscal year ended December 31, 2023 (FY2023).
Headline figures
Fiscal year ended December 31, 2023, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $103.78M
- up 94.0% from $53.51M a year earlier
- Net income
- $22.81M
- compared with a net loss of $46.42M a year earlier
- Diluted EPS
- $0.43
- compared with -$1.23 a year earlier